试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-23
WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism
编号:NCT03297359登记状态:提前终止企业 / 申办者:Ottawa Hospital Research Institute
药物 / 成分:Dalteparin
登记的停止原因(原文):Low recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-23
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
编号:NCT03740724登记状态:提前终止企业 / 申办者:Castle Creek Biosciences, LLC.
药物 / 成分:FCX-013、veledimex
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-23
Atomoxetine in Patients With Tourette's Syndrome
编号:NCT04354103登记状态:提前终止企业 / 申办者:Poitiers University Hospital
药物 / 成分:Atomoxetine
登记的停止原因(原文):experimental treatment (Atomoxetine) not available
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-23
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
编号:NCT05189977登记状态:提前终止企业 / 申办者:Otsuka Pharmaceutical Development & Commercialization, Inc.
药物 / 成分:Propranolol、Prazosin
登记的停止原因(原文):The decision to terminate the trial early was not based on safety concerns. The trial was terminated early due to some implausible blood pressure values being captured, which was the primary endpoint of the study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-23
Distal Radius Steroid
编号:NCT05655130登记状态:提前终止企业 / 申办者:Indiana Hand to Shoulder Center
药物 / 成分:Dexamethasone、Methylprednisolone、Standard of Care
登记的停止原因(原文):Low participation rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-22
Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
编号:NCT03500874登记状态:提前终止企业 / 申办者:Sun Yat-sen University
药物 / 成分:FUDR、Oxaliplatin、Leucovorin、5FU
登记的停止原因(原文):The study was terminated prematurely due to FUDR production halt in China
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-22
Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD
编号:NCT04446182登记状态:提前终止企业 / 申办者:University of Utah
药物 / 成分:Itacitinib、Extracorporeal Photopheresis (ECP)
登记的停止原因(原文):PI left institution
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-22
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
编号:NCT05162131登记状态:提前终止企业 / 申办者:SFJ Pharmaceuticals, Inc.
药物 / 成分:Bentracimab (PB2452) 100 mg or Placebo、Bentracimab (PB2452) 300 mg or Placebo、Bentracimab (PB2452) 1000 mg or Placebo、Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)
登记的停止原因(原文):After recruitment of Cohorts 1-4 was completed, Sponsor decided to terminate study, initially due to COVID and then considering that PK data from the dose planned to be tested in Cohort 5 (18000 mg) would be available from the ongoing Phase 3 study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-22
Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma
编号:NCT05262101登记状态:提前终止企业 / 申办者:Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
药物 / 成分:TQB2858 injection
登记的停止原因(原文):The sponsor has decided to terminate this study based on the current clinical research status of dual antibody drugs and full communication with the investigators.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-19
Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients
编号:NCT04941183登记状态:提前终止企业 / 申办者:Neutrolis
药物 / 成分:NTR-441、Placebo
登记的停止原因(原文):the emergence of the omicron variant of COVID-19 lead to insufficient enrollment
查看官方原始记录 ↗